OTC:PHBI
Pharmagreen Biotech Inc.
A high-risk biotech firm with negligible revenue but a large cash reserve from financing activities, currently operating at a substantial net loss.
Key Metrics
Investment Thesis
Bull Case
Bullish investors might view PHBI as a deep-value speculative play given its substantial paid-in capital and recent financing inflows that could fund a future breakthrough product or partnership. The company's ability to raise over $300k in financing cash flow suggests potential access to private markets despite public market struggles, offering an asymmetric upside if a commercial milestone is reached.
Bear Case
Bearish investors should avoid PHBI due to its negative shareholders' equity of -$1.8M and a retained earnings deficit of $-12.6M, indicating a potentially insolvent balance sheet. With zero revenue, massive operating losses, and cash reserves that are actively depleting, the company faces an imminent risk of delisting or requiring dilutive restructuring.
About Pharmagreen Biotech Inc.
Pharmagreen Biotech Inc. (PHBI) is a biotechnology entity operating in the healthcare sector, focusing on research and development initiatives with minimal current revenue generation as indicated by zero reported sales. The company maintains a substantial paid-in capital base of approximately $10.3 million while managing significant operational deficits and accumulated retained earnings losses. Its financial profile suggests an early-stage or highly speculative venture dependent on future financing events to sustain operations.
Analysis
Management Discussion
Management has reported a net loss of $-875,505 for the period, driven by operating expenses of roughly $1.1 million against no revenue, resulting in a negative operating profit. Despite generating positive cash flow from financing activities of $313,708, the company burned through cash from operations totaling -$426,568, leading to a depletion of its cash reserves.
Industry Overview
The biotechnology industry is characterized by high failure rates, lengthy development cycles, and significant capital requirements before products reach market. Companies in this space often operate with negative earnings for years while investing heavily in R&D, but PHBI's lack of any revenue stream places it at the extreme risk end of this spectrum.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Operating Expenses | $1.1M |
| Operating Income | $-1.1M |
| G&A | $65.6K |
| Other OpEx | $1.0M |
| Non-Operating Income | $0 |
| Pre-Tax Income | $-1.1M |
| Income Tax | $0 |
| Continuing Ops | $-1.1M |
| Discontinued Ops | $0 |
| Net Income | $-875.5K |
| Minority Interest | $0 |
| Net to Common | $-875.5K |
| Metric | 2022 |
|---|---|
| Total Assets | $209.0K |
| Current Liabilities | $1.9M |
| Accounts Payable | $645.0K |
| Other Current Liab | $1.3M |
| Long-Term Liabilities | $119.5K |
| Total Liabilities | $2.0M |
| Shareholders' Equity | $-1.8M |
| Paid-In Capital | $10.3M |
| Retained Earnings | $-12.6M |
| AOCI | $93.8K |
| Total L&E | $209.0K |
| Metric | 2022 |
|---|---|
| Net Income (CFO) | $-875.5K |
| Non-Cash Adjustments | $499.9K |
| Working Capital Changes | $-51.0K |
| Cash from Operations | $-426.6K |
| Cash from Investing | $0 |
| Cash from Financing | $313.7K |
| FX Effect | $95.6K |
| Net Change in Cash | $-17.3K |
| Beginning Cash | $25.3K |
| Ending Cash | $8.0K |
Frequently Asked Questions
How does Pharmagreen Biotech Inc. make money?
The company's financials indicate a lack of diversified revenue streams, as cost of revenue and gross profit are both zero, suggesting operations are confined to research, development, or administrative functions without commercialized product sales in the latest reporting period.
What are the main risks for PHBI?
The primary risks include severe liquidity constraints with a net change in cash of -$17k and ending cash of only $8k, a massive accumulated deficit of -$12.6M threatening solvency, zero revenue generation creating a dependency on external capital, and high operating expenses relative to the lack of income.
What is PHBI's competitive advantage?
Potential advantages include access to significant paid-in capital of $10.3 million which provides a runway for R&D, and the ability to generate cash from financing activities exceeding $300k, though these are offset by heavy operating burn.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.